Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin

被引：2
|
作者：
Pettus, Jeremy
Vajda, Eric G.
Pipkin, James
Williamson, Gretchen
Zangmeister, Miriam A.
Li, Yong-Xi
Henry, Robert R.
D'Alessio, David
Frias, Juan P.
Zhi, Lin
Marschke, Keith
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-73-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] 12-week treatment with glucagon receptor antagonist LY2409021 significantly lowers HbA1c and is well tolerated in patients with type 2 diabetes mellitus
    Kazda, C. M.
    Garhyan, P.
    Kelly, R. P.
    Shi, C.
    Lim, C. N.
    Fu, H.
    Deeg, M.
    DIABETOLOGIA, 2012, 55 : S51 - S52
  • [2] 12-Week Treatment With Glucagon Receptor Antagonist LY2409021 Signifi cantly Lowers HbA1c and is Well Tolerated in Patients With T2DM
    Kazda, Christof
    Garhyan, Parag
    Kelly, Ronan P.
    Shi, Chunxue
    Lim, Chay Ngee
    Fu, Haoda
    Deeg, Mark
    DIABETES, 2012, 61 : A250 - A250
  • [3] The Glucagon Receptor Antagonist LY2409021 Significantly Lowers HbA1c and Is Well Tolerated in Patients With T2DM: A 24-Week Phase 2 Study
    Kazda, Christof
    Headlee, Stacey
    Ding, Ying
    Kelly, Ronan P.
    Garhyan, Parag
    Hardy, Thomas A.
    Lewin, Andrew
    DIABETES, 2013, 62 : A29 - A29
  • [4] The glucagon receptor antagonist LY2409021 significantly lowers HbA1c and is well tolerated in patients with type 2 diabetes mellitus: a 24-week phase 2 study
    Kazda, C. M.
    Headlee, S. A.
    Ding, Y.
    Kelly, R. P.
    Garhyan, P.
    Hardy, T. A.
    Lewin, A. J.
    DIABETOLOGIA, 2013, 56 : S391 - S392
  • [5] LGD-6972, a Potent, Orally-Bioavailable, Small Molecule Glucagon Receptor Antagonist for the Treatment of Type 2 Diabetes
    Vajda, Eric G.
    Potter, Scott C.
    Fujitaki, James M.
    Reddy, Raja K.
    Van Poelje, Paul D.
    Lee, Yong-Hee
    Henderson, Ian
    Zhi, Lin
    Marschke, Keith B.
    DIABETES, 2012, 61 : A252 - A252
  • [6] Modelling HbA1c Trajectory in Patients with Type 2 Diabetes Mellitus (T2DM)
    Mcewan, Phil
    Fellows, Jonathan
    Yapp, Rhiannon
    Bergenheim, Klas
    Qin, Lei
    Varol, Nebibe
    Bennett, Hayley
    Gordon, Jason
    DIABETES, 2016, 65 : A322 - A322
  • [7] Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus
    Vajda, Eric G.
    Logan, Douglas
    Lasseter, Kenneth
    Armas, Danielle
    Plotkin, Diane J.
    Pipkin, J. D.
    Li, Yong-Xi
    Zhou, Rong
    Klein, David
    Wei, Xiaoxiong
    Dilzer, Stacy
    Zhi, Lin
    Marschke, Keith B.
    DIABETES OBESITY & METABOLISM, 2017, 19 (01): : 24 - 32
  • [8] Treatment Progression and Impact of HbA1C in Type 2 Diabetes (T2DM) Patients
    Dibello, Julia R.
    Levy, Brian
    Mehra, Maneesha
    DIABETES, 2010, 59 : A623 - A624
  • [9] Clustering of HBA1C longitudinal trajectories in type 2 diabetes mellitus (T2DM)
    De la Torre, Adrian Martinez
    Faquetti, Maria Luisa Marques De Sa
    Perez-Cruz, Fernando
    Weiler, Stefan
    Burden, Andrea
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 60 - 60
  • [10] Abnormally low HbA1c in type 2 diabetes mellitus (T2DM): Familiar study
    Gargallo, Manuel A.
    Familiar, Cristina
    Gonzalez, Fernando A.
    Villegas, Ana
    DIABETES, 2006, 55 : A112 - A113
12345